Massachusetts General Hospital SAFER criteria for clinical trials and research.
about
A Phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients.Guarding the Gate: Remote Structured Assessments to Enhance Enrollment Precision in Depression Trials.The role of regulators, investigators, and patient participants in the rise of the placebo response in major depressive disorder.Mavoglurant Augmentation in OCD Patients Resistant to Selective Serotonin Reuptake Inhibitors: A Proof-of-Concept, Randomized, Placebo-Controlled, Phase 2 Study.
P2860
Massachusetts General Hospital SAFER criteria for clinical trials and research.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Massachusetts General Hospital SAFER criteria for clinical trials and research.
@en
Massachusetts General Hospital SAFER criteria for clinical trials and research.
@nl
type
label
Massachusetts General Hospital SAFER criteria for clinical trials and research.
@en
Massachusetts General Hospital SAFER criteria for clinical trials and research.
@nl
prefLabel
Massachusetts General Hospital SAFER criteria for clinical trials and research.
@en
Massachusetts General Hospital SAFER criteria for clinical trials and research.
@nl
P2093
P1476
Massachusetts General Hospital SAFER criteria for clinical trials and research.
@en
P2093
Christina Dording
David Mischoulon
Heidi Ashih
Janet Witte
Maren Nyer
Marlene P Freeman
Maurizio Fava
Nadia Iovieno
P304
P356
10.1097/HRP.0B013E3182A75CC7
P577
2013-09-01T00:00:00Z